Tricor (fenofibrate) is a leading prescription medication specifically formulated to address dyslipidemia—an imbalance of lipids in the bloodstream. As a fibric acid derivative, it targets elevated triglyceride levels and optimizes cholesterol profiles by increasing high-density lipoprotein (HDL) while reducing low-density lipoprotein (LDL) and very-low-density lipoprotein (VLDL). Clinically proven and widely trusted, Tricor plays a critical role in comprehensive cardiovascular risk reduction strategies, especially for patients with mixed dyslipidemia or those intolerant to statin therapy. Its targeted mechanism offers a specialized approach to lipid regulation, supporting long-term vascular health.

Features

• Active ingredient: Fenofibrate (micronized formulation for enhanced bioavailability)
• Available in multiple strengths: 48 mg and 145 mg tablets
• FDA-approved for the treatment of severe hypertriglyceridemia and primary hypercholesterolemia
• Works by activating peroxisome proliferator-activated receptor-alpha (PPAR-α)
• Reduces hepatic production of triglycerides and promotes lipoprotein lipase activity
• Improves clearance of triglyceride-rich particles from plasma
• Can be used as monotherapy or in combination with statins under medical supervision
• Once-daily dosing regimen for patient convenience

Benefits

• Significantly lowers elevated triglyceride levels, reducing the risk of pancreatitis
• Increases HDL (“good”) cholesterol, supporting reverse cholesterol transport
• Modifies LDL particle size to a less atherogenic phenotype
• Contributes to overall cardiovascular risk management when combined with diet and lifestyle changes
• May slow the progression of coronary atherosclerosis in certain patient populations
• Offers a therapeutic alternative for patients with statin intolerance or specific lipid abnormalities

Common use

Tricor is primarily indicated for the treatment of adults with severe hypertriglyceridemia (triglycerides ≥500 mg/dL) to reduce the risk of pancreatitis. It is also used in patients with primary hypercholesterolemia or mixed dyslipidemia to lower LDL cholesterol, total cholesterol, triglycerides, and apolipoprotein B, and to increase HDL cholesterol. It is often prescribed when response to dietary therapy and other non-pharmacological measures has been inadequate. Tricor may be used alone or in combination with other lipid-lowering agents, particularly in patients who require additional triglyceride reduction beyond what statins provide.

Dosage and direction

The recommended dosage of Tricor is individualized based on patient lipid levels and treatment response. The usual dose for adults is 145 mg once daily, though some patients may be started on 48 mg daily. Tablets should be swallowed whole with a full glass of water and may be taken with or without food, though consistency in administration relative to meals is recommended. Dosage should be adjusted based on periodic lipid determinations, with the minimum effective dose used to achieve the desired lipid levels. Renal impairment requires dosage adjustment: for eGFR 30-59 mL/min, the maximum dose is 48 mg daily; for eGFR below 30 mL/min, use is contraindicated. Liver function should be monitored before and during treatment.

Precautions

Before starting Tricor, patients should undergo complete lipid profiling, liver function tests, renal function assessment, and gallbladder studies. Regular monitoring of liver enzymes (ALT, AST) is required during therapy, with discontinuation if levels persist above 3 times the upper limit of normal. Pancreatitis may develop despite triglyceride reduction, requiring immediate evaluation if abdominal pain occurs. Tricor may increase cholesterol excretion into bile, potentially leading to cholelithiasis. Muscle toxicity, including myositis and rhabdomyolysis, may occur, particularly in elderly patients and those with renal impairment, hypothyroidism, or concomitant statin use. Ophthalmologic examinations are recommended as fenofibrate may cause cataract formation. Serum creatinine levels should be monitored as increases have been observed during treatment.

Contraindications

Tricor is contraindicated in patients with hypersensitivity to fenofibrate or any component of the formulation; those with hepatic impairment, including primary biliary cirrhosis and unexplained persistent liver function abnormalities; severe renal impairment (eGFR <30 mL/min); gallbladder disease; nursing mothers; and pediatric patients. Concomitant use with repaglinide is contraindicated due to increased risk of severe hypoglycemia. It should not be used during pregnancy unless clearly needed, as fetal harm may occur.

Possible side effect

Common side effects (≥2%) include: increased liver enzymes, abdominal pain, back pain, headache, respiratory disorders, nausea, constipation, and diarrhea. Less frequent but clinically significant adverse reactions may include: pancreatitis, hepatitis, cirrhosis, increased creatine phosphokinase, rhabdomyolysis, myopathy, arthralgia, dizziness, insomnia, pruritus, rash, urticaria, photosensitivity, decreased hemoglobin, anemia, leukopenia, thrombocytopenia, increased serum creatinine, renal impairment, erectile dysfunction, and blurred vision. Serious but rare events include pulmonary embolism, deep vein thrombosis, and Stevens-Johnson syndrome.

Drug interaction

Tricor may potentiate the effects of oral anticoagulants (warfarin), requiring frequent INR monitoring and dosage adjustment. Bile acid sequestrants reduce fenofibrate absorption and should be administered at least 2 hours apart. Cyclosporine increases fenofibrate exposure and should be avoided. Concomitant use with statins increases the risk of myopathy and rhabdomyolysis. Fenofibrate may increase the exposure of some glitazones and ezetimibe. It may alter thyroid function test results in patients on thyroid replacement therapy. The hypoglycemic effect of sulfonylureas and insulin may be potentiated. Immunosuppressants, niacin, and other fibrates may increase the risk of adverse effects when combined with Tricor.

Missed dose

If a dose of Tricor is missed, it should be taken as soon as remembered on the same day. If it is almost time for the next scheduled dose, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not take a double dose to make up for a missed one. Consistency in daily dosing is important for maintaining stable lipid levels, but occasional missed doses are unlikely to significantly impact long-term treatment efficacy. Patients should discuss any pattern of missed doses with their healthcare provider.

Overdose

There is limited experience with Tricor overdose. Symptoms may include abdominal discomfort, nausea, vomiting, and reversible increases in liver function tests. In cases of suspected overdose, supportive and symptomatic treatment should be initiated. There is no specific antidote for fenofibrate overdose. Hemodialysis is unlikely to be effective due to high protein binding, but appropriate supportive measures should be implemented based on clinical presentation. Medical toxicology consultation is recommended for significant overdoses. Patients should be monitored for potential muscle and liver toxicity.

Storage

Tricor tablets should be stored at room temperature (20-25°C or 68-77°F) in their original container, protected from light, moisture, and excessive heat. Keep the medication out of reach of children and pets. Do not store in bathrooms or near kitchen sinks where moisture levels may be high. Discard any medication that has expired or is no longer needed through medication take-back programs or according to FDA-recommended disposal methods. Do not flush medications down the toilet unless specifically instructed to do so.

Disclaimer

This information is provided for educational purposes only and does not constitute medical advice. Tricor is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual results may vary, and not all patients will experience the same benefits or side effects. Patients should not discontinue or change their dosage without consulting their physician. The full prescribing information should be consulted before initiating therapy. This summary does not include all possible information about Tricor and cannot replace professional medical advice, diagnosis, or treatment.

Reviews

Clinical studies demonstrate that Tricor effectively reduces triglyceride levels by 40-50% and increases HDL cholesterol by 15-25% in most patients. The ACCORD Lipid trial showed that fenofibrate added to statin therapy provided particular benefit to patients with high triglycerides and low HDL levels. Many physicians report satisfactory lipid control in appropriate patient populations, with particular success in those with isolated hypertriglyceridemia. Patient reviews often mention improved lipid panel results and general tolerability, though some report gastrointestinal discomfort during the initial treatment period. Long-term users appreciate the once-daily dosing convenience. Dermatologists occasionally note improved xanthoma resolution in patients on Tricor therapy.